Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1984 2
1985 1
1987 4
1988 3
1990 4
1991 3
1993 5
1994 4
1995 6
1996 3
1997 6
1998 9
1999 4
2000 3
2001 3
2002 6
2003 10
2004 3
2005 6
2006 5
2007 4
2008 8
2009 13
2010 10
2011 15
2012 6
2013 17
2014 12
2015 13
2016 17
2017 14
2018 14
2019 16
2020 18
2021 15
2022 9
Text availability
Article attribute
Article type
Publication date

Search Results

267 results
Results by year
Filters applied: . Clear all
Page 1
Myasthenia gravis: from autoantibodies to therapy.
Mantegazza R, Bernasconi P, Cavalcante P. Mantegazza R, et al. Curr Opin Neurol. 2018 Oct;31(5):517-525. doi: 10.1097/WCO.0000000000000596. Curr Opin Neurol. 2018. PMID: 30156572 Review.
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.
Howard JF Jr, Bril V, Vu T, Karam C, Peric S, Margania T, Murai H, Bilinska M, Shakarishvili R, Smilowski M, Guglietta A, Ulrichts P, Vangeneugden T, Utsugisawa K, Verschuuren J, Mantegazza R; ADAPT Investigator Study Group. Howard JF Jr, et al. Among authors: mantegazza r. Lancet Neurol. 2021 Jul;20(7):526-536. doi: 10.1016/S1474-4422(21)00159-9. Lancet Neurol. 2021. PMID: 34146511 Clinical Trial.
Diagnosis and treatment of myasthenia gravis.
Mantegazza R, Cavalcante P. Mantegazza R, et al. Curr Opin Rheumatol. 2019 Nov;31(6):623-633. doi: 10.1097/BOR.0000000000000647. Curr Opin Rheumatol. 2019. PMID: 31385879 Review.
Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis.
Howard JF Jr, Bril V, Burns TM, Mantegazza R, Bilinska M, Szczudlik A, Beydoun S, Garrido FJRR, Piehl F, Rottoli M, Van Damme P, Vu T, Evoli A, Freimer M, Mozaffar T, Ward ES, Dreier T, Ulrichts P, Verschueren K, Guglietta A, de Haard H, Leupin N, Verschuuren JJGM; Efgartigimod MG Study Group. Howard JF Jr, et al. Among authors: mantegazza r. Neurology. 2019 Jun 4;92(23):e2661-e2673. doi: 10.1212/WNL.0000000000007600. Epub 2019 May 22. Neurology. 2019. PMID: 31118245 Free PMC article. Clinical Trial.
COVID-19-associated risks and effects in myasthenia gravis (CARE-MG).
Muppidi S, Guptill JT, Jacob S, Li Y, Farrugia ME, Guidon AC, Tavee JO, Kaminski H, Howard JF Jr, Cutter G, Wiendl H, Maas MB, Illa I, Mantegazza R, Murai H, Utsugisawa K, Nowak RJ; CARE-MG Study Group. Muppidi S, et al. Among authors: mantegazza r. Lancet Neurol. 2020 Dec;19(12):970-971. doi: 10.1016/S1474-4422(20)30413-0. Lancet Neurol. 2020. PMID: 33212055 Free PMC article. No abstract available.
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
Howard JF Jr, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Muppidi S, Nowak RJ, O'Brien F, Wang JJ, Mantegazza R; REGAIN Study Group. Howard JF Jr, et al. Among authors: mantegazza r. Lancet Neurol. 2017 Dec;16(12):976-986. doi: 10.1016/S1474-4422(17)30369-1. Epub 2017 Oct 20. Lancet Neurol. 2017. PMID: 29066163 Clinical Trial.
Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic.
International MG/COVID-19 Working Group, Jacob S, Muppidi S, Guidon A, Guptill J, Hehir M, Howard JF Jr, Illa I, Mantegazza R, Murai H, Utsugisawa K, Vissing J, Wiendl H, Nowak RJ. International MG/COVID-19 Working Group, et al. Among authors: mantegazza r. J Neurol Sci. 2020 May 15;412:116803. doi: 10.1016/j.jns.2020.116803. Epub 2020 Mar 25. J Neurol Sci. 2020. PMID: 32247193 Free PMC article. No abstract available.
Long-term safety and efficacy of eculizumab in generalized myasthenia gravis.
Muppidi S, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Nowak RJ, Andersen H, Casasnovas C, de Bleecker JL, Vu TH, Mantegazza R, O'Brien FL, Wang JJ, Fujita KP, Howard JF Jr; Regain Study Group. Muppidi S, et al. Among authors: mantegazza r. Muscle Nerve. 2019 Jul;60(1):14-24. doi: 10.1002/mus.26447. Epub 2019 Mar 8. Muscle Nerve. 2019. PMID: 30767274 Free PMC article.
Nusinersen safety and effects on motor function in adult spinal muscular atrophy type 2 and 3.
Maggi L, Bello L, Bonanno S, Govoni A, Caponnetto C, Passamano L, Grandis M, Trojsi F, Cerri F, Ferraro M, Bozzoni V, Caumo L, Piras R, Tanel R, Saccani E, Meneri M, Vacchiano V, Ricci G, Soraru' G, D'Errico E, Tramacere I, Bortolani S, Pavesi G, Zanin R, Silvestrini M, Politano L, Schenone A, Previtali SC, Berardinelli A, Turri M, Verriello L, Coccia M, Mantegazza R, Liguori R, Filosto M, Marrosu G, Siciliano G, Simone IL, Mongini T, Comi G, Pegoraro E. Maggi L, et al. Among authors: mantegazza r. J Neurol Neurosurg Psychiatry. 2020 Nov;91(11):1166-1174. doi: 10.1136/jnnp-2020-323822. Epub 2020 Sep 11. J Neurol Neurosurg Psychiatry. 2020. PMID: 32917822
267 results